Antibody–drug conjugates in non-small cell lung cancer: current landscape and future directions
This review summarizes the latest clinical progress of ADCs in NSCLC, highlighting key agents and their impact, while also addressing the associated challenges and future directions for optimizing this promising treatment modality.